celecoxib has been researched along with caffeic acid in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, QH; Knaus, EE; Rao, PN | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR | 2 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Rahman, M; Suresh, MR | 1 |
| Coy, ED; Cuca, LE; Sefkow, M | 1 |
| Aparoy, P; Chandramohan Reddy, T; Kalangi, SK; Kumar Reddy, K; Reddanna, P | 1 |
| Chen, SH; Gu, LQ; Huang, ZS; Li, D; Li, Y; Ou, TM; Tan, JH | 1 |
| Cai, H; Huang, X; Huang, Y; Jiang, B; Jiang, J; Shen, H; Sun, Y; Wu, X; Xu, J; Xu, S; Yao, H; Zhang, P | 1 |
| Chlapek, P; Hermanova, M; Loja, T; Redova, M; Sterba, J; Veselska, R; Zitterbart, K | 1 |
| Chlapek, P; Hermanova, M; Redova, M; Sterba, J; Veselska, R; Zitterbart, K | 1 |
| Chlapek, P; Chovanova, S; Krzyzankova, M; Neradil, J; Radsetoulal, M; Sterba, J; Veselska, R; Zitterbart, K | 1 |
| Dash, S; Kar, D; Ray, M; Sahrawat, TR; Shahbazi, S; Singh, S | 1 |
| Arab, HH; Eid, AH; Fikry, EM; Gad, AM | 1 |
| Arora, D; Kinra, M; Mallikarjuna Rao, C; Mudgal, J; Nampoothiri, M; Pai, KSR | 1 |
14 other study(ies) available for celecoxib and caffeic acid
| Article | Year |
|---|---|
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Lipoxygenase Inhibitors; Mice; Models, Molecular; Pain Measurement; Rats; Structure-Activity Relationship | 2006 |
Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Design; Edema; Foot; Lipoxygenase Inhibitors; Molecular Structure; Pyrazoles; Pyridones; Rats; Structure-Activity Relationship; Sulfonamides | 2008 |
Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Ibuprofen; Inflammation; Inhibitory Concentration 50; Isoenzymes; Lipoxygenase Inhibitors; Models, Chemical; Pyridones; Rats | 2009 |
Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Pyrazoles; Spectrophotometry, Infrared; Sulfonamides | 2009 |
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Lauraceae; Lipoxygenase Inhibitors; Platelet Aggregation Inhibitors; Rabbits | 2009 |
Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Lipoxygenase Inhibitors; Models, Chemical; Models, Molecular | 2010 |
Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
Topics: Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Benzoates; Binding Sites; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Lipoxygenase Inhibitors; Structure-Activity Relationship; Sulfonamides | 2011 |
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Lipoxygenase Inhibitors; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship; Triazoles | 2016 |
Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines.
Topics: Apoptosis; Caffeic Acids; Celecoxib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Shape; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Humans; Lipoxygenase Inhibitors; Neuroblastoma; Pyrazoles; Sulfonamides; Tretinoin | 2010 |
Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.
Topics: Brain Neoplasms; Caffeic Acids; Celecoxib; Cell Differentiation; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lipoxygenase Inhibitors; Multigene Family; Neuroblastoma; Oxidative Stress; Pyrazoles; Sulfonamides; Tretinoin | 2010 |
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Caffeic Acids; Celecoxib; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Humans; Lipoxygenase Inhibitors; Osteosarcoma; Pyrazoles; Sulfonamides; Tretinoin | 2014 |
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
Topics: Anti-Inflammatory Agents; Aspirin; Binding Sites; Caffeic Acids; Celecoxib; Coumaric Acids; Cyclooxygenase 1; Cyclooxygenase 2; ERG1 Potassium Channel; Eugenol; Heart; Humans; Inflammation; Integrin alpha2; Protein Structure, Tertiary; Tirofiban; Tyrosine | 2016 |
Caffeic acid and ellagic acid ameliorate adjuvant-induced arthritis in rats via targeting inflammatory signals, chitinase-3-like protein-1 and angiogenesis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Caffeic Acids; Celecoxib; Chitinase-3-Like Protein 1; Drug Therapy, Combination; Ellagic Acid; Inflammation Mediators; Male; Neovascularization, Pathologic; Random Allocation; Rats; Rats, Sprague-Dawley | 2019 |
Effect of Caffeic Acid on Ischemia-Reperfusion-Induced Acute Renal Failure in Rats.
Topics: Acute Kidney Injury; Animals; Antioxidants; Arachidonate 5-Lipoxygenase; Blood Urea Nitrogen; Caffeic Acids; Celecoxib; Creatinine; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Lipid Peroxidation; Male; Oxidative Stress; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2019 |